References
- Alam F, Al-Hilal TA, Chung SW, et al. (2014). Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials 35:6543–52.
- Arbit E. (2004). The physiological rationale for oral insulin administration. Diabetes Technol 6:510–7.
- Chuang EY, Lin KJ, Lin PY, et al. (2015). Self-assembling bubble carriers for oral protein delivery. Biomaterials 64:115–24.
- Du H, Liu M, Yang X, Zhai G. (2015). The design of pH-sensitive chitosan-based formulations for gastrointestinal delivery. Drug Discov Today 20:1004–11.
- Edgerton DS, Lautz M, Scott M, et al. (2006). Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 116:521–7.
- Fan W, Xia D, Zhu Q, et al. (2018). Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials 151:13–23.
- Geho WB, Geho HC, Lau JR, Gana TJ. (2009). Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 3:1451–9.
- Gong YZ, Everett ET, Schwartz DA, et al. (1994). Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. Proc Natl Acad Sci 91:4741–5.
- Ho NFH. (1987). Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann N Y Acad Sci 507:315–29.
- Hsu LW, Ho YC, Chuang EY, et al. (2013). Effects of pH on molecular mechanisms of chitosan-integrin interactions and resulting tight-junction disruptions. Biomaterials 34:784–93.
- IDF Diabetes Atalas. (2017). International Diabetes Federation, Available at: http://www.idf.org/diabetesatlas.
- Khatun Z, Nurunnabi, Cho KJ, et al. (2014). Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. J Control Release 177:64–73.
- Kolhatkar V, Polli JE. (2012). Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. Eur J Pharm Sci 46:86–99.
- Li Z, Hu X, Jiang J, et al. (2018). Recent advances in closed-loop and smart insulin delivery systems. Chin J Org Chem 38:29–39.
- Lopes MA, Abrahim BA, Seiça R, et al. (2014). Intestinal uptake of insulin nanoparticles: facts or myths? Curr Pharm Biotechnol 15:629–38.
- Makhlof A, Tozuka Y, Takeuchi H. (2011). Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci 42:445–51.
- Mcginn BJ, Morrison JD. (2016). Investigations into the absorption of insulin and insulin derivatives from the small intestine of the anaesthetised rat. J Control Release 232:120–30.
- Mo R, Jiang T, Di J, et al. (2014). Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev 43:3595–629.
- Pessin JE, Saltiel AR. (2000). Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165–9.
- Saltiel AR, Kahn CR. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806.
- Schadt HS, Wolf A, Pognan F, et al. (2016). Bile acids in drug induced liver injury: key players and surrogate markers. Clin Res Hepatol Gastroenterol 40:257–66.
- Sheng J, He H, Han L, et al. (2016). Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates. J Control Release 233:181–90.
- Singh B, Maharjan S, Jiang T, et al. (2015). Attuning hydroxypropyl methylcellulose phthalate to oral delivery vehicle for effective and selective delivery of protein vaccine in ileum. Biomaterials 59:144–59.
- Swaan PW, Szoka FC, Øie S. (1996). Use of the intestinal and hepatic bile acid transporters for drug delivery. Adv Drug Deliv Rev 20:59–82.
- Wang X, Shi C, Zhang L, et al. (2016). Affinity-controlled protein encapsulation into sub-30 nm telodendrimer nanocarriers by multivalent and synergistic interactions. Biomaterials 101:258–71.
- Zambito Y, Felice F, Fabiano A, et al. (2013). Mucoadhesive nanoparticles made of thiolated quaternary chitosan crosslinked with hyaluronan. Carbohydr Polym 92:33–9.
- Zhang D, Li D, Shang L, et al. (2016a). Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption. Int J Pharm 511:161–9.
- Zhang Z, Cai H, Liu Z, Yao P. (2016b). Effective enhancement of hypoglycemic effect of insulin by liver-targeted nanoparticles containing cholic acid-modified chitosan derivative. Mol Pharm 13:2433–42.